RNS Number: 0016B Cambridge Cognition Holdings PLC 20 August 2024



20 August 2024

# **Cambridge Cognition Holdings plc**

("Cambridge Cognition", the "Company" or the "Group")

#### **Notice of Results**

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, will announce its unaudited interim results for the six months ended 30 June 2024 on Thursday 22 August 2024.

### **Enquiries:**

**Cambridge Cognition Holdings plc**Matthew Stork, Chief Executive Officer

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Freddy Crossley / Mark Rogers Rupert Dearden

**Dowgate Capital Limited (Joint Broker)** 

David Poutney / James Serjeant

**Hudson Sandler (Financial PR and IR)** 

Dan de Belder / Hattie Dreyfus

Tel: 012 2381 0700

Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking)

Tel: 020 3903 7715

Tel: 020 7796 4133 cog@hudsonsandler.com

# **Notes to Editors**

# **About Cambridge Cognition**

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit: <a href="https://cambridgecognition.com/">https://cambridgecognition.com/</a>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:rns@lseq.com">rns@lseq.com</a> or visit <a href="www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBCGDILBBDGSC